Humira Biosimilars in 2026: Every Brand, Interchangeability, Cost

If your pharmacy handed you a box that says Hyrimoz or Yuflyma instead of Humira, you are holding one of ten FDA-approved adalimumab products, and the differences between them are smaller than the paperwork suggests. This is the brand-by-brand reference for every Humira biosimilar available to Crohn's patients in 2026, built from the FDA's own product listings. If you are new to the topic, our guide to biosimilars for Crohn's disease covers the basics first.

Key Takeaways

• Ten adalimumab biosimilars to Humira hold FDA approval, from Amjevita in September 2016 to Simlandi in February 2024 (1)
• Nine of the ten carry the FDA's interchangeable licence type; Idacio (adalimumab-aacf) is licensed as a biosimilar only (2)
• Interchangeability is recorded per presentation, not per brand, so your exact strength matters more than the name on the box (2)
• Yuflyma and Simlandi come only in high concentration (100 mg/mL); Abrilada, Hulio and Idacio only in low concentration (50 mg/mL) (2)
• In the only prospective Crohn's study of biosimilar-to-biosimilar switching, switch success at 6 months was 82.0% and retention 88.5%, though adverse events rose from 1.6% to 11.5% (4)
• Employer plan costs per prescription ranged from $639 for Yusimry to $2,655 for Amjevita in 2024 claims data, before rebates (5)

The Full List: All 10 Humira Biosimilars the FDA Has Approved

The FDA has licensed ten adalimumab biosimilars referencing Humira, spanning September 2016 to February 2024 (1). Each is a 351(k) biosimilar, meaning the FDA found it highly similar to Humira with no clinically meaningful differences in safety, purity or potency. What separates them is licence type, concentration, device design and price, not whether the molecule works.

The brand-by-brand table

| Brand name | Nonproprietary name | Manufacturer | FDA approval | |---|---|---|---| | Amjevita | adalimumab-atto | Amgen | September 2016 | | Cyltezo | adalimumab-adbm | Boehringer Ingelheim | August 2017 | | Hyrimoz | adalimumab-adaz | Sandoz | October 2018 | | Hadlima | adalimumab-bwwd | Samsung Bioepis | July 2019 | | Abrilada | adalimumab-afzb | Pfizer | November 2019 | | Hulio | adalimumab-fkjp | Biocon Biologics | July 2020 | | Yusimry | adalimumab-aqvh | Emerge Bioscience | December 2021 | | Idacio | adalimumab-aacf | Fresenius Kabi | December 2022 | | Yuflyma | adalimumab-aaty | Celltrion | May 2023 | | Simlandi | adalimumab-ryvk | Alvotech | February 2024 |

Every value above comes from the FDA's Biosimilar Product Information page (1) and the Purple Book September 2026 data file (2). An eleventh adalimumab name on a pharmacy label is almost certainly a private-label version of one of these ten, covered in the pricing section below.

Why every name ends in a four-letter suffix

Many of us have looked at "adalimumab-bwwd" and assumed the letters meant something clinical. They do not. The FDA assigns each biosimilar a unique four-letter suffix after the shared core name so pharmacies, insurers and adverse-event reporting systems can tell the products apart. It is not a grade or a quality score.

One thing to know before you panic at a discontinuation notice: a single brand can have several presentations, and some older ones are marked discontinued in the Purple Book while the brand is still marketed. Abrilada and Hyrimoz both show a mix as of the September 2026 data (2). So a discontinuation notice sometimes means one strength went away, not the whole product. Which of these ten you can get is decided by your insurer's formulary, not by this list.

Interchangeable or Just Biosimilar: What the Label Lets a Pharmacist Do

An interchangeable biosimilar has cleared a higher bar than a standard biosimilar: the manufacturer had to show the product can be expected to produce the same clinical result as Humira in any given patient, and that switching back and forth does not raise safety risks or reduce effectiveness (3). Nine of the ten adalimumab biosimilars now hold that designation (2).

What the interchangeable designation actually means

A 351(k) biosimilar is approved as highly similar to its reference product with no clinically meaningful differences. An interchangeable biosimilar has also met the switching standard above (3).

The practical consequence is the part that affects your pharmacy pickup. In the FDA's own words, the interchangeable designation "may allow pharmacists to substitute the biosimilar product for the reference product without consulting the prescribing health care provider, subject to state pharmacy law" (3). That is why you can be handed a different box without a new prescription.

Which nine are interchangeable, and the one that is not

As of the September 2026 Purple Book data, nine adalimumab biosimilars carry the interchangeable licence type: Amjevita, Cyltezo, Hyrimoz, Hadlima, Abrilada, Hulio, Yusimry, Yuflyma and Simlandi. Idacio (adalimumab-aacf) is still licensed as a biosimilar only (2). The two most recent additions to the interchangeable list are Hadlima, with an interchangeable approval date of April 29, 2026, and Yusimry, on August 28, 2026 (2).

Here is the nuance most roundup articles get wrong: interchangeability is recorded per presentation, not per brand name. Several products carry different interchangeable approval dates for different strengths (2). Look up your exact strength in the Purple Book rather than assuming the whole brand is covered.

Why your state law still has the last word

The FDA decides whether a product may be substituted. Pharmacy law where you live decides how: some jurisdictions require prescriber notification, some patient notification, some neither. Outside the United States the concept itself differs by regulator, and some systems handle substitution through hospital tendering instead.

For scale, the FDA had licensed 89 biosimilar products as of August 2026, 42 designated interchangeable (3). Adalimumab is the most crowded family in that count, which is why brand switches land in Crohn's inboxes so often.

High Concentration, Low Concentration and Citrate-Free

Concentration is the one difference between biosimilars you can feel. A 40 mg dose in 0.4 mL is 100 mg/mL, the high-concentration formulation. The same 40 mg in 0.8 mL is 50 mg/mL, the low-concentration one. Same amount of drug, half the liquid, and a shorter injection.

How to read the strength on your box

Divide the milligrams by the millilitres printed on the carton or pen. If you get 100, it is high concentration. If you get 50, it is low. For how adalimumab itself works and its dosing schedule, see our article on Humira and adalimumab for Crohn's disease.

Which brands come in which concentration

Sorting by the strengths listed in the Purple Book September 2026 data (2):

• High concentration only: Yuflyma (10 mg/0.1 mL, 20 mg/0.2 mL, 40 mg/0.4 mL, 80 mg/0.8 mL) and Simlandi (20 mg/0.2 mL, 40 mg/0.4 mL, 80 mg/0.8 mL)
• Low concentration only: Abrilada, Hulio and Idacio
• Both concentrations: Amjevita, Cyltezo, Hyrimoz, Hadlima and Yusimry, which added a 40 mg/0.4 mL presentation in 2026

Citrate-free status is widely claimed and rarely sourced. Citrate buffer is associated with injection stinging, and the high-concentration versions of adalimumab are the citrate-free ones. Yuflyma was specifically approved as a high-concentration (100 mg/mL) and citrate-free biosimilar (7). For any other brand, the inactive ingredients list on your package insert is the only place that settles it.

For context, a rheumatologist quoted by HCPLive estimated that more than 80% of patients treated with Humira in the United States rely on a high-concentration, citrate-free formulation (7). That is an attributed expert estimate, not a measured statistic.

The practical takeaway: a move from a high-concentration product to a low-concentration one doubles your injection volume and may sting more. That is worth raising with your GI team, and it is often fixable by asking for a different biosimilar rather than refusing biosimilars altogether. If injections are already hard, our guide to needle anxiety with biologic injections covers techniques that help.

What Switching From One Brand to Another Actually Feels Like

In the only prospective Crohn's-specific study of biosimilar-to-biosimilar adalimumab switching, 61 patients were analysed and 43 of them (70.5%) were multiple switchers who had gone from Humira to one biosimilar and then on to a second. Switch success at 6 months, defined as no steroids, no discontinuation and no dose escalation, was 82.0%, and retention on the new product was 88.5% (4).

What the Crohn's switching data shows

Those are reassuring numbers, and we will not smooth over the part that is not. Adverse events were more common in the 6 months after the switch than the 6 months before: 7 of 61 patients (11.5%) versus 1 (1.6%), p=0.03. The events were asthenia, injection-site pain, peripheral arthritis, three skin reactions and abdominal pain, with no life-threatening events reported (4).

Two findings are directly actionable. Having switched more than once did not predict failure (p=0.91), which matters for anyone on their second or third brand. And a CRP above 5 mg/L at the time of the switch was the only significant predictor of failure in the multivariate model (4), a concrete reason to ask for bloodwork before agreeing to a non-urgent switch rather than during a flare.

The limits matter: single centre, 61 patients, no endoscopic outcomes. It is the best Crohn's-specific brand-to-brand evidence available, and still a small study.

The part nobody warns you about: the device changes

In our community, the complaint that comes up most after a brand switch is almost never the molecule. It is the pen. Autoinjector shape, needle gauge, plunger resistance, dose window, grip size and latex-free status all vary between brands, so a new brand means re-learning the injection you had finally stopped dreading. The FDA itself has flagged delivery-device differences between an interchangeable biosimilar and its reference product as an open development problem (3).

A short monitoring plan makes the switch an informed one rather than a leap:

1. Write down the date of your first dose of the new brand
2. Log symptoms, stool frequency and injection-site reactions for two cycles
3. Ask for a CRP or faecal calprotectin check 8 to 12 weeks after the switch, so you have an objective number to compare rather than a feeling

How the Money Works: List Price, Private Label and What You Pay

Biosimilar competition has not automatically translated into savings at the counter. In its 2026 strategy document the FDA notes that anticipated cost savings have not fully materialised due to rebate structures and formulary positioning (3). Three different numbers are in play: list price, net price after rebates, and what you actually pay.

Why two identical drugs cost four times as much

Nomi Health's analysis of 2024 prescription claims from 956 self-funded employers found adalimumab biosimilar cost per prescription ranged from $639 for Yusimry to $2,655 for Amjevita, with Hadlima at $929 and Hyrimoz at $1,455 (5), checked October 8, 2026. These are pre-rebate amounts paid by employer health plans, not what a patient pays at the counter and not the list price either. That four-fold spread for clinically equivalent molecules shows that formulary placement, not chemistry, drives the number on your bill.

The unbranded and PBM private-label versions

Increasingly, patients are handed a box matching none of the ten brand names. Cordavis, owned by CVS Health, markets a Cordavis-labelled version of Sandoz's Hyrimoz. Quallent, part of Cigna's Evernorth, markets products made by Boehringer Ingelheim and by Alvotech and Teva, one sold simply as adalimumab-adbm at a list price of $1,315, roughly 81% below Humira's list price, as reported in September 2024 (6), checked October 8, 2026. These are the same FDA-approved molecules under a different label, and 2024 prices may have changed.

What to do about your own out-of-pocket cost

• Check whether your plan's preferred product is a branded, unbranded or private-label version
• Ask the specialty pharmacy which exact product and strength will ship, before it ships
• Look up copay assistance for that specific brand, since programmes do not transfer
• Ask about the manufacturer's patient assistance programme if you are uninsured

Here is the trap: a copay card tied to your old brand stops working the moment your plan switches brands, which is how patients get a surprise bill on a drug that is supposed to be cheaper. Re-enrol in the new brand's programme before the first fill, and if the switch is driven by a formulary exclusion, our article on prior authorization and appeals for Crohn's disease covers the exception mechanics.

Coverage rules vary enormously between countries, so readers outside the United States should treat these dollar figures as illustrative of the spread rather than local pricing.

Your Plan Switched Your Brand: Questions to Ask This Week

If a letter arrived telling you your adalimumab brand is changing, six questions cover almost everything. Ask your GI team or specialty pharmacy: which exact product and strength is this, is it interchangeable for that strength, is it high or low concentration, is it citrate-free, is the device the same kind of autoinjector, and who covers the copay now.

For the insurer or pharmacy benefit manager: is this a formulary exclusion or a therapeutic substitution, is there a medical exception process, and what documentation would the GI team need to provide. The prior authorization and appeals guide walks through how those appeals are written.

Pushing back is reasonable in some situations: an active flare, a recent dose escalation, a CRP above 5 mg/L (4), or a move from a high-concentration citrate-free product to a low-concentration one when injections are already a struggle. Pushing back means asking for a different biosimilar or a change in timing, not refusing biosimilars as a class.

The honest bottom line for 2026: nine of the ten adalimumab biosimilars now meet the FDA's interchangeability standard (2), the Crohn's-specific switching data is reassuring even where it is imperfect (4), and the real friction is paperwork, devices and pricing rather than whether the molecule works.

Frequently Asked Questions

Is a Humira biosimilar as effective as Humira for Crohn's disease?

The FDA approves each adalimumab biosimilar only after finding no clinically meaningful differences from Humira in safety, purity and potency (1). In the prospective Crohn's switching study, 82.0% of patients met the 6-month switch success definition and 88.5% stayed on the new product (4). The practical differences are device, concentration and cost.

Which Humira biosimilars are interchangeable in 2026?

Nine of the ten: Amjevita, Cyltezo, Hyrimoz, Hadlima, Abrilada, Hulio, Yusimry, Yuflyma and Simlandi. Idacio (adalimumab-aacf) remains licensed as a biosimilar only (2). Because interchangeability is recorded per presentation, look up your specific strength rather than assuming the whole brand qualifies.

Can my pharmacy switch my brand without telling my doctor?

If the product is designated interchangeable, the FDA says the designation "may allow pharmacists to substitute the biosimilar product for the reference product without consulting the prescribing health care provider, subject to state pharmacy law" (3). So it depends on where you live: some jurisdictions require prescriber or patient notification, others do not.

How do I know if my adalimumab is high or low concentration?

Divide the milligrams by the millilitres on your carton. 40 mg in 0.4 mL is 100 mg/mL, high concentration. 40 mg in 0.8 mL is 50 mg/mL, low (2). Yuflyma and Simlandi are high concentration only; Abrilada, Hulio and Idacio low concentration only.

Will switching biosimilars make my injection hurt more?

It can, if the switch moves you from a high-concentration product to a low-concentration one, because the injection volume doubles. Citrate buffer is also associated with stinging, and the high-concentration formulations are the citrate-free ones (7). Injection-site pain was among the adverse events reported after switching in the Crohn's study (4).

What happens to my copay card when my brand changes?

It stops working. Copay assistance programmes are run by individual manufacturers for individual brands and do not transfer when your plan switches you. Re-enrol in the new brand's programme before your first fill, and ask the specialty pharmacy which exact product will ship so you enrol in the right one.

References

1. U.S. Food and Drug Administration. Biosimilar Product Information. 2026. Read article
2. U.S. Food and Drug Administration. Purple Book Database of Licensed Biological Products, September 2026 monthly data file. 2026. Search the Purple Book
3. U.S. Food and Drug Administration. BsUFA III Future Needs for the Development of Interchangeable Products: Post-Workshop Strategy Document. 2026. Read document
4. Ribaldone DG, et al. Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. 2021. Read study
5. Nomi Health. Humira Biosimilars Range from $639 to $2,655 Per Prescription: What Self-Funded Employers Are Actually Paying. 2025. Read article
6. Drug Channels. Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble?. September 2024. Read article
7. HCPLive. FDA Approves High-Concentration, Citrate-Free Biosimilar Adalimumab-aaty. 2023. Read article